Although VEGF-A inhibitors, such as bevacizumab and aflibercept, and VEGFR-2 inhibitors, such as sunitinib, were investigated in prostate cancer patients, they failed because of a lack of efficacy and side-effects [34]. This evidence concerns the gene KDR and Familial prostate cancer.